65,437 trials
Cataract
Primary: Posterior Capsule Opacification Evaluation — 3; 28 participants
Hepatitis C
Primary: Number of Participants With Vaccine-related Clinical (Systemic and Injection-site), and Laboratory Adverse Events (AE) — 5; 1; 3; 1 Participants
Acne Vulgaris
Primary: Change From Baseline (Log10 Cfu/cm²) in Count of Follicular P. Acnes — -1.94; -1.56 Log10 cfu/cm²
Spondylitis, Ankylosing
Primary: Mean Time Interval Between Remicade Infusions in Participants During Maintenance Treatment Following Induction Therapy — 56.10; 60.62; 57.91; 59.39 Days
Type 2 Diabetes Mellitus
Primary: Number of Participants With Adverse Events. — 1; 5; 8; 5 participants
HIV-1 · HIV Infections
Primary: Number of Participants With Adverse Experiences — 20; 13; 36; 33 Participants
Hepatitis A Virus
Primary: Seropositivity Rate (SPR) to Hepatitis A — 100; 100; 100; 100 Percentage of participants
Foetal Growth Problem · Small for Gestational Age
Primary: Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 260 - Subjects Received NN220 Treatment for 5 Years — -2.9488; -2.9047; 1.2066; 2.0247…
Cancer
Primary: Number of Patients With ALT (Alanine Transaminase) >=3x (Times) Upper Limit of Normal (ULN) — 11 participants
Liver Cirrhosis, Biliary
Primary: DB Phase: Mean Percent Change In Serum Alkaline Phosphatase (ALP) From Baseline To Day 85 — -44.5; -37.6; 0.4 Percent change — p=<0.0001
Breast Neoplasm
Primary: Number of Participants With Infusion Reactions (IR) — 7 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD) — 0; 0; 1; 0 Dose Limiting Toxicity (DLT)
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4) — -1.775; -2.434 mmol/L
Post Herpetic Neuralgia · PHN · Neuropathy
Primary: Change in Pain Scores Comparing NP-1 Cream vs. Placebo Cream for Treatment of the Pain of Post Herpetic Neuralgia(PHN)From Baseline to 28 Days. — 2.424; 2.471; 1.877…
Healthy
Primary: Number of Participants With Detectable C-Reactive Protein (CRP) — 16; 8 participants with CRP above 0.3 — p=.009